Rubicon Research's Remarkable Profit Surge and IPO Plans

Rubicon Research, a pharmaceutical formulations company, has announced a 69% rise in profit after tax, reaching Rs 43.3 crore for the quarter ending June 2025. This represents a significant leap from Rs 25.56 crore recorded in the same period last year.

The company, which focuses on innovation through research and development, sees its total income climbing to Rs 357 crore, compared to Rs 322 crore in the previous year's April-June quarter. These developments come as Rubicon prepares to launch its initial public offering (IPO) by October, following SEBI's approval.

Amansa Investments recently invested Rs 250 crore in the firm via pre-IPO funding. The company's forthcoming IPO includes a Rs 500 crore fresh issue of equity shares, with plans to use proceeds for debt payment, strategic acquisitions, and other corporate purposes.

(With inputs from agencies.)